Cholesterol metabolism altered and FGF21 levels high after pediatric liver transplantation despite normal serum lipids

American Journal of Transplantation

Volumn 12, Issue 10, 2012, Pages 2815-2824

  Kosola, S ^a   Lampela, H ^a   Gylling, H ^a   Jalanko, H ^a   Nissinen, M J ^a   Lauronen, J ^a   Makisalo H ^b   Vaaralahti, K ^c   Miettinen, T A ^a   Raivio, T ^c   Pakarinen, M P ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^c BIOMEDICUM HELSINKI   (Finland)

Author keywords

Cholesterol; immunosuppression; lipids; long term outcomes; pediatric liver transplantation

Indexed keywords

AZATHIOPRINE; CAMPESTEROL; FIBROBLAST GROWTH FACTOR 21; LATHOSTEROL; LIPID; LIPOPROTEIN; METHYLPREDNISOLONE; SITOSTEROL; STEROL;

ADOLESCENT; ADULT; ARTICLE; CARDIOVASCULAR RISK; CHILD; CHOLESTEROL SYNTHESIS; CLINICAL ARTICLE; CONTROLLED STUDY; DISORDERS OF CHOLESTEROL METABOLISM; FEMALE; HUMAN; INTESTINE ABSORPTION; LIPID BLOOD LEVEL; LIPOPROTEIN BLOOD LEVEL; LIVER TRANSPLANTATION; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SURVIVOR;

ADOLESCENT; ADULT; CHILD; CHOLESTEROL; FEMALE; FIBROBLAST GROWTH FACTORS; HUMANS; LIVER TRANSPLANTATION; MALE; YOUNG ADULT;

EID: 84867097076     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2012.04147.x     Document Type: Article

References (46)

1. Johnston SD, Morris JK, Cramb R, Gunson BK, Neuberger J,. Cardiovascular morbidity and mortality after orthotopic liver transplantation. Transplantation 2002; 73: 901-906.
2. McDiarmid SV, Gornbein JA, Fortunat M, et al,. Serum lipid abnormalities in pediatric liver transplant patients. Transplantation 1992; 53: 109-115.
3. Saab S, Shpaner A, Zhao Y, et al,. Prevalence and risk factors for diabetes mellitus in moderate term survivors of liver transplantation. Am J Transplant 2006; 6: 1890-1895.
4. Becker J, Huber WD, Aufricht C,. Short- and long-time effects of pediatric liver transplantation on serum cholesterol and triglyceride levels-the Vienna cohort. Pediatr Transplant 2008; 12: 883-888.
5. Marchetti P, Navalesi R,. The metabolic effects of cyclosporin and tacrolimus. J Endocrinol Invest 2000; 23: 482-490.
6. Padbury RT, Gunson BK, Dousset B, et al,. Steroid withdrawal from long-term immunosuppression in liver allograft recipients. Transplantation 1993; 55: 789-794.
7. Reding R, Gras J, Sokal E, Otte JB, Davies HF,. Steroid-free liver transplantation in children. Lancet 2003; 362: 2068-2070.
8. Diem HV, Sokal EM, Janssen M, Otte JB, Reding R,. Steroid withdrawal after pediatric liver transplantation: A long-term follow-up study in 109 recipients. Transplantation 2003; 75: 1664-1670.
9. Miettinen TA, Gylling H, Nissinen MJ,. The role of serum non-cholesterol sterols as surrogate markers of absolute cholesterol synthesis and absorption. Nutr Metab Cardiovasc Dis 2011; 21: 765-769.
10. Miettinen TA, Tilvis RS, Kesaniemi YA,. Serum plant sterols and cholesterol precursors reflect cholesterol absorption and synthesis in volunteers of a randomly selected male population. Am J Epidemiol 1990; 131: 20-31.
11. Miettinen TA, Gylling H, Raitakari OT, Hallikainen M, Viikari J,. Adolescent cholesterol metabolism predicts coronary risk factors at middle age: The Cardiovascular Risk in Young Finns Study. Transl Res 2008; 151: 260-266.
12. Nissinen MJ, Gylling H, Miettinen TA,. Effects of dietary cholesterol and fat on serum non-cholesterol sterols according to different apolipoprotein E subgroups among healthy men. Br J Nutr 2008; 100: 373-379.
13. Miettinen TA, Gylling H, Hallikainen M, et al,. Relation of non-cholesterol sterols to coronary risk factors and carotid intima-media thickness: The Cardiovascular Risk in Young Finns Study. Atherosclerosis 2010; 209: 592-597.
14. Simonen PP, Gylling H, Miettinen TA,. The distribution of squalene and non-cholesterol sterols in lipoproteins in type 2 diabetes. Atherosclerosis 2007; 194: 222-229.
15. Simonen P, Kotronen A, Hallikainen M, et al,. Cholesterol synthesis is increased and absorption decreased in non-alcoholic fatty liver disease independent of obesity. J Hepatol 2011; 54: 153-159.
16. Miettinen TA, Gylling H, Viikari J, Lehtimaki T, Raitakari OT,. Synthesis and absorption of cholesterol in Finnish boys by serum non-cholesterol sterols: The cardiovascular risk in Young Finns Study. Atherosclerosis 2008; 200: 177-183.
17. Siirtola A, Ketomaki A, Miettinen TA, et al,. Cholesterol absorption and synthesis in pediatric kidney, liver, and heart transplant recipients. Transplantation 2006; 81: 327-334.
18. Kharitonenkov A, Shiyanova TL, Koester A, et al,. FGF-21 as a novel metabolic regulator. J Clin Invest 2005; 115: 1627-1635.
19. Xu J, Lloyd DJ, Hale C, et al,. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259.
20. Dushay J, Chui PC, Gopalakrishnan GS, et al,. Increased fibroblast growth factor 21 in obesity and nonalcoholic fatty liver disease. Gastroenterology 2010; 139: 456-463.
21. Chavez AO, Molina-Carrion M, Abdul-Ghani MA, Folli F, Defronzo RA, Tripathy D,. Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance. Diabetes Care 2009; 32: 1542-1546.
22. Li H, Fang Q, Gao F, et al,. Fibroblast growth factor 21 levels are increased in nonalcoholic fatty liver disease patients and are correlated with hepatic triglyceride. J Hepatol 2010; 53: 934-940.
23. Lin Z, Zhou Z, Liu Y, et al,. Circulating FGF21 levels are progressively increased from the early to end stages of chronic kidney diseases and are associated with renal function in Chinese. PLoS One 2011; 6: e18398.
24. Ryden M,. Fibroblast growth factor 21: An overview from a clinical perspective. Cell Mol Life Sci 2009; 66: 2067-2073.
25. Hero M, Dunkel L, Vaaralahti K, Raivio T,. Serum FGF21 in boys with idiopathic short stature: Relationship to lipid profile, onset of puberty and growth. Clin Endocrinol (Oxf) 2011. doi: 10.1111/j.1365-2265.2011.03999.x. [Epub ahead of print]
26. Saari A, Sankilampi U, Hannila ML, Kiviniemi V, Kesseli K, Dunkel L,. New Finnish growth references for children and adolescents aged 0 to 20 years: Length/height-for-age, weight-for-length/height, and body mass index-for-age. Ann.Med 2011; 43: 235-248.
27. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC,. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
28. Laish I, Braun M, Mor E, Sulkes J, Harif Y, Ari ZB,. Metabolic syndrome in liver transplant recipients: Prevalence, risk factors, and association with cardiovascular events. Liver Transpl 2011; 17: 15-22.
29. Friedewald WT, Levy RI, Fredrickson DS,. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
30. Miettinen TA,. Cholesterol metabolism during ketoconazole treatment in man. J Lipid Res 1988; 29: 43-51.
31. Intraobserver and interobserver variations in liver biopsy interpretation in patients with chronic hepatitis C. The French METAVIR Cooperative Study Group. Hepatology 1994; 20 (1 Pt 1): 15-20.
32. Banff Working Group, Demetris AJ, Adeyi O, et al,. Liver biopsy interpretation for causes of late liver allograft dysfunction. Hepatology 2006; 44: 489-501.
33. Galman C, Lundasen T, Kharitonenkov A, et al,. The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man. Cell Metab 2008; 8: 169-174.
34. Mraz M, Bartlova M, Lacinova Z, et al,. Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity. Clin Endocrinol (Oxf) 2009; 71: 369-375.
35. Pihlajamaki J, Gylling H, Miettinen TA, Laakso M,. Insulin resistance is associated with increased cholesterol synthesis and decreased cholesterol absorption in normoglycemic men. J Lipid Res 2004; 45: 507-512.
36. Aberg F, Jula A, Hockerstedt K, Isoniemi H,. Cardiovascular risk profile of patients with acute liver failure after liver transplantation when compared with the general population. Transplantation 2010; 89: 61-68.
37. Bianchi G, Marchesini G, Marzocchi R, Pinna AD, Zoli M,. Metabolic syndrome in liver transplantation: Relation to etiology and immunosuppression. Liver Transpl 2008; 14: 1648-1654.
38. Flechner SM, Kobashigawa J, Klintmalm G,. Calcineurin inhibitor-sparing regimens in solid organ transplantation: Focus on improving renal function and nephrotoxicity. Clin Transplant 2008; 22: 1-15.
39. Dell-Olio D, Kelly DA,. Calcineurin inhibitor minimization in pediatric liver allograft recipients. Pediatr Transplant 2009; 13: 670-681.
40. Tredger JM, Brown NW, Dhawan A,. Calcineurin inhibitor sparing in paediatric solid organ transplantation: Managing the efficacy/toxicity conundrum. Drugs 2008; 68: 1385-1414.
41. Ng VL, Alonso EM, Bucuvalas JC, et al,. Health status of children alive 10 years after pediatric liver transplantation performed in the US and Canada: Report of the Studies of Pediatric Liver Transplantation Experience. J Pediatr 2012; 5: 820-826.
42. Sinclair NR,. Low-dose steroid therapy in cyclosporine-treated renal transplant recipients with well-functioning grafts. The Canadian Multicentre Transplant Study Group. CMAJ 1992; 147: 645-657.
43. Steiner RW, Awdishu L,. Steroids in kidney transplant patients. Semin Immunopathol 2011; 33: 157-167.
44. Siirtola A, Antikainen M, Ala-Houhala M, et al,. Serum lipids in children 3 to 5 years after kidney, liver, and heart transplantation. Transpl Int 2004; 17: 109-119.
45. Uebanso T, Taketani Y, Yamamoto H, et al,. Liver X receptor negatively regulates fibroblast growth factor 21 in the fatty liver induced by cholesterol-enriched diet. J Nutr Biochem 2011. Sep 1. [Epub ahead of print]
46. Beaven SW, Wroblewski K, Wang J, et al,. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology 2011; 140: 1052-1062.